acetylated peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-14. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
== Side effects == Nausea, ejaculation failure, insomnia, diarrhea, dry mouth, somnolence, dizziness, tremor, headache, excessive sweating, fatigue, restless legs syndrome and decreased libido are the common adverse effects associated with sertraline with the greatest difference from placebo. Those that most often result in interruption of the treatment are nausea, diarrhea, and insomnia. The incidence of diarrhea is higher with sertraline – especially when prescribed at higher doses – in comparison with other SSRIs. Over more than six months of sertraline therapy for depression, people showed no significant weight increase. A 30-month-long treatment with sertraline for OCD also resulted in no significant weight gain. Although the difference did not reach statistical significance, the average weight gain was lower for fluoxetine (1%) but higher for citalopram, fluvoxamine and paroxetine (2.5%). Of the sertraline group, 4.5% gained a large amount of weight (defined as more than 7% gain). This result compares favorably with placebo, where, according to the literature, 3–6% of patients gained more than 7% of their initial weight. The large weight gain was observed only among female members of the sertraline group; the significance of this finding is unclear because of the small size of the group. Over a two-week treatment of healthy volunteers, sertraline slightly improved verbal fluency but did not affect word learning, short-term memory, vigilance, flicker fusion time, choice reaction time, memory span, or psychomotor coordination.
{\displaystyle {\begin{aligned}{\frac {dM}{dt}}&=\Lambda -\delta M-\mu M\\[6pt]{\frac {dS}{dt}}&=\delta M-{\frac {\beta SI}{N}}-\mu S\\[6pt]{\frac {dE}{dt}}&={\frac {\beta SI}{N}}-(\varepsilon +\mu )E\\[6pt]{\frac {dI}{dt}}&=\varepsilon E-(\gamma +\mu )I\\[6pt]{\frac {dR}{dt}}&=\gamma I-\mu R\end{aligned}}}
==== MeSH D12.125.095 – amino acids, diamino ==== MeSH D12.125.095.104 – arginine MeSH D12.125.095.104.075 – argininosuccinic acid MeSH D12.125.095.104.095 – benzoylarginine-2-naphthylamide MeSH D12.125.095.104.100 – benzoylarginine nitroanilide MeSH D12.125.095.104.400 – homoarginine MeSH D12.125.095.104.525 – ng-nitroarginine methyl ester MeSH D12.125.095.104.587 – nitroarginine MeSH D12.125.095.104.650 – omega-n-methylarginine MeSH D12.125.095.104.900 – tosylarginine methyl ester MeSH D12.125.095.165 – asparagine MeSH D12.125.095.226 – citrulline MeSH D12.125.095.307 – cystathionine MeSH D12.125.095.369 – cystine MeSH D12.125.095.390 – diaminopimelic acid MeSH D12.125.095.461 – glutamine MeSH D12.125.095.461.700 – proglumide MeSH D12.125.095.533 – homocystine MeSH D12.125.095.647 – lysine MeSH D12.125.095.647.478 – hydroxylysine MeSH D12.125.095.647.575 – lysinoalanine MeSH D12.125.095.647.750 – polylysine MeSH D12.125.095.765 – ornithine MeSH D12.125.095.765.340 – eflornithine
=== Wealth and assets === Morea has been listed in various publications among Indian film personalities with significant net worth. As of 2025, his net worth has been estimated at over US$150 million by some sources. He is reported to own several high-end vehicles, including models such as the Rolls Royce Ghost, BMW M8, Lamborghini Sián, Mercedes GLS, Porsche 911, Ford Endeavour, as well as motorcycles like the Harley-Davidson Forty-Eight, Royal Enfield Bullet 500, and Aprilia RSV4. Reports also indicate that he owns multiple residential properties in India and abroad.
Sources: en.wikipedia.org
Biden entered office nine months into a recovery from the COVID-19 recession and his first year in office was characterized by robust growth in real GDP, employment, wages, and stock market returns, amid significantly elevated inflation. Real GDP grew 5.9%, the fastest rate in 37 years. Amid record job creation, the unemployment rate fell at the fastest pace on record. By the end of 2021, inflation rates measured by the consumer price index (CPI) reached a nearly 40-year high of 7.1%, which was partially offset by the highest nominal wage and salary growth in at least 20 years. The inflation rate peaked at 9% in June 2022. The inflation rate reached 2.9% and core inflation rate reached 3.2% on an annual basis in December 2024, the last full month of Biden's term. Between December 2020 and December 2024, CPI rose 21.3% overall, with an annualized inflation rate of 5.3% throughout Biden's term in office. The inflation rate remained above the Federal Reserve's 2% target every month since March 2021, resulting in elevated interest rates to combat inflation. Average wages increased 19% throughout Biden's presidency, falling behind inflation. The unemployment rate declined by over 2% and real GDP grew 11% during Biden's term. Total household net worth increased by 28%, largely driven by stocks and real estate. The national debt grew to $36.2 trillion, with a debt to GDP ratio of 123% and a deficit to GDP ratio of 6% in FY 2024. In February 2023, the unemployment rate fell to 3.4%, a 53-year low.
==== First-episode psychosis ==== First-episode psychosis (FEP) is the first time that psychotic symptoms are presented. NICE recommends that all people presenting with first-episode psychosis be treated with both an antipsychotic drug and cognitive behavioral therapy (CBT). NICE further recommends that those expressing a preference for CBT alone be informed that combination treatment is more effective. A diagnosis of schizophrenia is not made at this time as it takes longer to be determined by both DSM-5 and ICD-11, and only around 60% of those presenting with a first episode of psychosis will later be diagnosed with schizophrenia. The conversion rate for a first episode of drug induced psychosis to bipolar disorder or schizophrenia is lower, with 30% of people converting to either bipolar disorder or schizophrenia. NICE makes no distinction between substance-induced psychosis and any other form of psychosis. The rate of conversion differs for different classes of drugs. Pharmacological options for the specific treatment of FEP have been discussed in recent reviews. The goals of treatment for FEP include reducing symptoms and potentially improving long-term treatment outcomes. Randomized clinical trials have provided evidence for the efficacy of antipsychotic drugs in achieving the former goal, with first-generation and second generation antipsychotics showing about equal efficacy. The evidence that early treatment has a favorable effect on long-term outcomes is equivocal.
Rush started to deviate from its 1980s style with the albums Presto (1989) and Roll the Bones (1991). Produced by record engineer and musician Rupert Hine, these two albums saw Rush shedding much of its keyboard-saturated sound. Beginning with Presto, the band opted for arrangements notably more guitar-centric than the previous two studio albums. Although synthesizers were still used, they were no longer featured as the centre-piece of Rush's compositions. Continuing this trend, Roll the Bones extended the use of the standard three-instrument approach with even less focus on synthesizers than its predecessor. While musically these albums do not deviate significantly from a general pop-rock sound, Rush incorporated other musical styles such as funk and hip-hop in "Roll the Bones" and jazz in the instrumental track "Where's My Thing?". "Show Don't Tell" from Presto was a No. 1 hit on the US Mainstream Rock Tracks Chart, and while the album reached the Top 10 in Canada, it was less successful in the US (No. 16) and the UK (No. 27). From Roll the Bones, "Dreamline" (No. 1) and "Ghost of a Chance" (No. 2) were successful on US Mainstream Rock Radio stations, marking a resurgence of Rush's album sales in the US (No. 3 and platinum), the UK (No. 10) and some other parts of northern Europe. The transition from synthesizers to more guitar-oriented and organic instrumentation continued with Counterparts (1993) and its follow-up, Test for Echo (1996), both produced in collaboration with Peter Collins.
The double “A” refers to the nickname “All American Division” adopted by the organization during World War I. The newly formed unit was composed of members, who came from all across all 48 states and given the nickname “All-American.” The shoulder sleeve insignia was redesigned for the 82nd Airborne Division and an Airborne tab was added on top, authorized on August 31, 1942.
== U == Ultradian rhythm A recurrent biological cycle that occurs more than once in 24 hours, such as stages of sleep. In neuroscience, it refers to shorter rhythms regulating hormonal release, arousal, or sleep cycles. Unconditioned response In classical conditioning, an automatic, reflexive response to an unconditioned stimulus (e.g., salivation to food). Studied in behavioral neuroscience. Unconsciousness A state in which an individual is not aware of themselves or their surroundings. Can result from head injury, anesthesia, or metabolic dysfunction. Uncus A structure on the medial surface of the temporal lobe, part of the parahippocampal gyrus. It is involved in olfaction and is adjacent to the amygdala. Undershoot The hyperpolarizing phase following an action potential where membrane potential temporarily becomes more negative than resting potential. Unilateral neglect A neuropsychological condition following damage (typically to the right parietal lobe) in which patients ignore stimuli on one side of space. Unipolar depression A mood disorder characterized by persistent low mood, lack of energy, and anhedonia, without manic episodes. Associated with altered activity in the prefrontal cortex and limbic structures. Unipolar neuron A type of neuron with a single process extending from the cell body. Common in invertebrates and found in human sensory neurons. Upper motor neuron A neuron originating in the cerebral cortex or brainstem that transmits motor signals to lower motor neurons. Damage leads to spasticity, hyperreflexia, and weakness.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.